|
1
|
Ganti AK, Klein AB, Cotarla I, Seal B and
Chou E: Update of incidence, prevalence, survival,and initial
treatment in patients with non-small cell lung cancer in the US.
JAMA Oncol. 7:1824–1832. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhou F, Guo H, Xia Y, Le X, Tan D,
Ramalingam SS and Zhou C: The changing treatment landscape of
EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol.
22:95–116. 2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mizuno T, Konno H, Nagata T, Isaka M and
Ohde Y: Osteogenic and brain metastases after non-small cell lung
cancer resection. Int J Clin Oncol. 26:1840–1846. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Popat S, Ahn MJ, Ekman S, Leighl NB,
Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL and Yang
JC: Osimertinib for EGFR-mutant non-small-cell lung cancer central
nervous system metastases: Current evidence and future perspectives
on therapeutic strategies. Target Oncol. 18:9–24. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li Z, Wang J, Deng L, Zhai Y, Zhang T, Bi
N, Wang J, Wang X, Liu W, Xiao Z, et al: Hippocampal avoidance
whole-brain radiotherapy with simultaneous integrated boost in lung
cancer brain metastases and utility of the Hopkins verbal learning
test for testing cognitive impairment in Chinese patients: A
prospective phase II study. BMC Cancer. 24(899)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gaebe K, Li AY, Park A, Parmar A, Lok BH,
Sahgal A, Chan K, Erickson AW and Das S: Stereotactic radiosurgery
versus whole brain radiotherapy in patients with intracranial
metastatic disease and small-cell lung cancer: A systematic review
and meta-analysis. Lancet Oncol. 23:931–939. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Le Rhun E, Guckenberger M, Smits M, Dummer
R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS,
Metellus P, et al: EANO-ESMO Clinical practice guidelines for
diagnosis, treatment and follow-up of patients with brain
metastasis from solid tumours. Ann Oncol. 32:1332–1347.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vogelbaum MA, Brown PD, Messersmith H,
Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson N,
Gondi V, et al: Treatment for brain metastases: ASCO-SNO-ASTRO
guideline. J Clin Oncol. 40:492–516. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Colclough N, Chen K, Johnström P,
Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnäs K,
Adua SJ, et al: Preclinical comparison of the blood-brain barrier
permeability of osimertinib with other EGFR TKIs. Clin Cancer Res.
27:189–201. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hayman JA, Dekker A, Feng M, Keole SR,
McNutt TR, Machtay M, Martin NE, Mayo CS, Pawlicki T, Smith BD, et
al: Minimum data elements for radiation oncology: An American
society for radiation oncology consensus paper. Pract Radiat Oncol.
9:395–401. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tozuka T, Noro R, Mizutani H, Kurimoto F,
Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C,
et al: Osimertinib plus local treatment for brain metastases versus
osimertinib alone in patients with EGFR-mutant non-small cell lung
cancer. Lung Cancer. 191(107540)2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tsai PF, Yang CC, Chuang CC, Huang TY, Wu
YM, Pai PC, Tseng CK, Wu TH, Shen YL and Lin SY: Hippocampal
dosimetry correlates with the change in neurocognitive function
after hippocampal sparing during whole brain radiotherapy: A
prospective study. Radiat Oncol. 10(253)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hanna N, Johnson D, Temin S, Baker S Jr,
Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl
NB, et al: Systemic therapy for stage IV non-small-cell lung
cancer: American society of clinical oncology clinical practice
guideline update. J Clin Oncol. 35:3484–3515. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hendriks LE, Kerr KM, Menis J, Mok TS,
Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et
al: Non-oncogene-addicted metastatic non-small-cell lung cancer:
ESMO Clinical practice guideline for diagnosis, treatment and
follow-up. Ann Oncol. 34:358–376. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schuler M, Wu YL, Hirsh V, O'Byrne K,
Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V and
Yang JCH: First-Line afatinib versus chemotherapy in patients with
non-small cell lung cancer and common epidermal growth factor
receptor gene mutations and brain metastases. J Thorac Oncol.
11:380–390. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yang JJ, Zhou C, Huang Y, Feng J, Lu S,
Song Y, Huang C, Wu G, Zhang L, Cheng Y, et al: Icotinib versus
whole-brain irradiation in patients with EGFR-mutant non-small-cell
lung cancer and multiple brain metastases (BRAIN): A multicentre,
phase 3, open-label, parallel, randomised controlled trial. Lancet
Respir Med. 5:707–716. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jung HA, Woo SY, Lee SH, Ahn JS, Ahn MJ,
Park K and Sun JM: The different central nervous system efficacy
among gefitinib, erlotinib and afatinib in patients with epidermal
growth factor receptor mutation-positive non-small cell lung
cancer. Transl Lung Cancer Res. 9:1749–1758. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Peng W, Pu X, Jiang M, Wang J, Li J, Li K,
Xu Y, Xu F, Chen B, Wang Q, et al: Dacomitinib induces objective
responses in metastatic brain lesions of patients with EGFR-mutant
non-small-cell lung cancer: A brief report. Lung Cancer. 152:66–70.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Reungwetwattana T, Nakagawa K, Cho BC,
Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, et
al: CNS response to osimertinib versus standard epidermal growth
factor receptor tyrosine kinase inhibitors in patients with
untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin
Oncol. 28(JCO2018783118)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheng Y, He Y, Li W, Zhang HL, Zhou Q,
Wang B, Liu C, Walding A, Saggese M, Huang X, et al: Osimertinib
versus comparator EGFR TKI as first-line treatment for EGFR-mutated
advanced NSCLC: FLAURA China, A randomized study. Target Oncol.
16:165–176. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III
trial of aumolertinib versus gefitinib as first-line therapy for
locally advanced or metastaticnon-small-cell lung cancer with EGFR
exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Furmonertinib (AST2818) versus
gefitinib as first-line therapy for Chinese patients with locally
advanced or metastatic EGFR mutation-positive non-small-cell lung
cancer (FURLONG): A multicentre, double-blind, randomised phase 3
study. Lancet Respir Med. 10:1019–1028. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Central nervous system efficacy
of furmonertinib (AST2818) versus gefitinib as first-line treatment
for EGFR-mutated NSCLC: Results from the FURLONG study. J Thorac
Oncol. 17:1297–1305. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu ST, Xi JJ, Zhong WZ, Mao WM, Wu L, Shen
Y, Liu YY, Chen C, Cheng Y, Xu L, et al: The unique
spatial-temporal treatment failure patterns of adjuvant gefitinib
therapy: A post hoc analysis of the ADJUVANT trial (CTONG 1104). J
Thorac Oncol. 14:503–512. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Patel SH, Rimner A, Foster A, Zhang Z, Woo
KM, Yu HA, Riely GJ and Wu AJ: Patterns of initial and intracranial
failure in metastatic EGFR-mutant non-small cell lung cancer
treated with erlotinib. Lung Cancer. 108:109–114. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou Y, Wang B, Qu J, Yu F, Zhao Y, Li S,
Zeng Y, Yang X, Chu L, Chu X, et al: Survival outcomes and
symptomatic central nervous system (CNS) metastasis in EGFR-mutant
advanced non-small cell lung cancer without baseline CNS
metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase
inhibitors. Lung Cancer. 150:178–185. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhao Y, Li S, Yang X, Chu L, Wang S, Tong
T, Chu X, Yu F, Zeng Y, Guo T, et al: Overall survival benefit of
osimertinib and clinical value of upfront cranial local therapy in
untreated EGFR-mutant nonsmall cell lung cancer with brain
metastasis. Int J Cancer. 150:1318–1328. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zeng Y, Su X, Zhao Y, Zhou Y, Guo T, Chu
X, Chu L, Yang X, Ni J and Zhu Z: Rationale and value of
consolidative cranial local therapy in EGFR-mutant non-small cell
lung cancer patients with baseline brain metastasis treated with
first-line EGFR-TKIs. Ther Adv Med Oncol.
15(17588359231169975)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Arvanitis CD, Ferraro GB and Jain RK: The
blood-brain barrier and blood-tumour barrier in brain tumours and
metastases. Nat Rev Cancer. 20:26–41. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tanaka H, Karita M, Ueda K, Ono T, Kajima
M, Manabe Y, Fujimoto K, Yuasa Y and Shiinoki T: Differences in
radiosensitivity according to egfr mutation status in non-small
cell lung cancer: A clinical and in vitro study. J Pers Med.
14(25)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen H, Wu A, Tao H, Yang D, Luo Y, Li S,
Yang Z and Chen M: Concurrent versus sequential whole brain
radiotherapy and TKI in EGFR-mutated NSCLC patients with brain
metastasis: A single institution retrospective analysis. Medicine
(Baltimore). 97(e13014)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Du XJ, Pan SM, Lai SZ, Xu XN, Deng ML,
Wang XH, Yao DC and Wu SX: Upfront cranial radiotherapy vs. EGFR
tyrosine kinase inhibitors alone for the treatment of brain
metastases from non-small-cell lung cancer: A meta-analysis of 1465
patients. Front Oncol. 8(603)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Magnuson WJ, Lester-Coll NH, Wu AJ, Yang
TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD,
et al: Management of brain metastases in tyrosine kinase
inhibitor-naïve epidermal growth factor receptor-mutant
non-small-cell lung cancer: A retrospective multi-institutional
analysis. J Clin Oncol. 35:1070–1077. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tancherla A, Wijovi F, Hariyanto TI,
Kurniawan A and Giselvania A: 142P EGFR-TKI plus radiotherapy
versus EGFR-TKI only in non-small cell lung cancer patients with
brain metastasis: A systematic review and meta-analysis of
observational studies. J Thorac Oncol. 16(S774)2021.
|
|
39
|
Miyawaki E, Kenmotsu H, Mori K, Harada H,
Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori
S, et al: Optimal sequence of local and EGFR-TKI therapy for
EGFR-mutant non-small cell lung cancer with brain metastases
stratified by number of brain metastases. Int J Radiat Oncol Biol
Phys. 104:604–613. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Goldstein IM, Roisman LC, Keren-Rosenberg
S, Dudnik J, Nechushtan H, Shelef I, Fuchs V, Kian W and Peled N:
Dose escalation of osimertinib for intracranial progression in EGFR
mutated non-small-cell lung cancer with brain metastases.
Neurooncol Adv. 1(vdaa125)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yu F, Ni J, Zeng W, Zhou Y, Guo T, Zeng Y,
Zhao Y, Li S, Li Y, Yang X, et al: Clinical value of upfront
cranial radiation therapy in osimertinib-treated epidermal growth
factor receptor-mutant non-small cell lung cancer with brain
metastases. Int J Radiat Oncol Biol Phys. 111:804–815.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhou J, Zhou Y, Sun Y, Xiao L, Lu H, Yin X
and Fan K: The efficacy of upfront craniocerebral radiotherapy and
epidermal growth factor receptor-tyrosine kinase inhibitors in
patients with epidermal growth factor receptor-positive non-small
cell lung cancer with brain metastases. Front Oncol.
13(1259880)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chen JY, Zhang H, Wang B, Wen J, Xu XY, Li
H and Fan M: 18P Stereotactic radiotherapy (SRT) in combination
with aumolertinib to treat intracranial oligometastatic non-small
cell lung cancer (NSCLC): An update of the phase II, prospective
study. J Thorac Oncol. 18(S51)2023.
|
